RESUMO
Objective To review pharmacological mechanism, pharmacokinetics, clinical research progress and prospects of pradefovir, a liver targeted medicine for hepatitis B.Methods The studies of pradefovir were summarized by searching literature databases of Web of Science,Elsevier ScienceDirect,Springer Link,Wiley Online Library, Pubmed, CNKI, Wanfang and VIP datebase.Results Pradefovir is a prodrug that targets to the liver, which absorbs rapidly by oral administration.Pradefovir could be quickly converted to adefovir with hepatic drug metabolizing enzyme CYP3A4. Compared with adefovir dipivoxil, it has shown smaller nephrotoxicity and larger liver targeting.Conclusion Pradefovir has shown favorable safety and effectiveness in the clinical study and has no durg resistance to be found.The approval Ⅲ clinical trial has been acquired of pradefovir in USA and has enteredⅠ clinical trial currently in our country, which has good prospects for clinical application in future.
RESUMO
A large number of literatures at home and abroad in recent years about Schisandrin B were viewed and its pharmacological effects were summarized. Schisandrin B has a variety of pharmacological activities, which can reduce transaminase activity in liver cells, inhibit lipid peroxidation, anti-oxidant, hepatoprotection, anti-tumor and so on. Its pharmacological effects are accurate and worthy of research and development as a potential drug.
